CRBP - Company ID 0001595097
The table below shows Corbus Pharmaceuticals Holdings, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $19.82M | $20.86M | $15.19M | $15.64M | $10.81M | $6.87M |
| SG&A |
Corbus Pharmaceuticals Holdings, Inc. reported annual revenue of $0.00 for fiscal year 2022. That is down 100.0% from $881.71K in fiscal 2021. Over the 8 fiscal years shown, annual revenue declined from $648.38K (FY 2015) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.49M |
| $3.56M |
| $3.96M |
| $4.13M |
| $4.70M |
| $4.12M |
| Operating income | -$24.30M | -$24.42M | -$19.15M | -$19.77M | -$15.51M | -$10.99M |
| Income tax | - | - | - | - | - | - |
| Net income | -$22.97M | -$23.34M | -$17.66M | -$16.98M | -$13.78M | -$10.00M |
| EPS (diluted) | -$1.23 | -$1.90 | -$1.44 | -$1.39 | -$1.15 | -$0.90 |